Rigel Appoints Michael P. Miller to the Board of Directors

Core Insights - Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors, bringing over 40 years of experience in the biotechnology and pharmaceutical industries [1][2]. Company Overview - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for patients with hematologic disorders and cancer [3]. - The company was founded in 1996 and is based in South San Francisco, California [3]. Leadership Appointment - Michael P. Miller's appointment is expected to enhance Rigel's strategic plan, particularly in growing its current portfolio and exploring in-licensing opportunities [2]. - Miller has held significant roles in various companies, including Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals and Senior Vice President at Vivus [2]. Strategic Vision - Miller expressed enthusiasm about joining Rigel, highlighting the company's evolution into a profitable entity with a strong commercial engine that supports a promising development pipeline [3]. - The focus will be on serving more patients with hematologic disorders and cancer, aligning with Rigel's mission [3].